Bexmarilimab (anti-STAB1) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC50 value of 4.51 nM. Bexmarilimab (anti-STAB1) is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab
Bexmarilimab (anti-STAB1) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC50 value of 4.51 nM. Bexmarilimab (anti-STAB1) is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab
Bexmarilimab (anti-STAB1) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC50 value of 4.51 nM. Bexmarilimab (anti-STAB1) is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab
Bexmarilimab (anti-STAB1) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC50 value of 4.51 nM. Bexmarilimab (anti-STAB1) is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab
Bimagrumab (anti-ACVR2B) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab (anti-ACVR2B) can be used for the research of pathological
Bimagrumab (anti-ACVR2B) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab (anti-ACVR2B) can be used for the research of pathological
Bimagrumab (anti-ACVR2B) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab (anti-ACVR2B) can be used for the research of pathological
Bimagrumab (anti-ACVR2B) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab (anti-ACVR2B) can be used for the research of pathological
Bimagrumab (anti-ACVR2B) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab (anti-ACVR2B) can be used for the research of pathological
Bimagrumab (anti-ACVR2B) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab (anti-ACVR2B) can be used for the research of pathological
Bimagrumab (anti-ACVR2B) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab (anti-ACVR2B) can be used for the research of pathological
Bimagrumab (anti-ACVR2B) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab (anti-ACVR2B) can be used for the research of pathological
Mouse anti Human CD14 Antibody, Monoclonal (UCHM1), could be used for Flow and so on.
Application:
Flow: < 0.5 μg/100w cells
Protein Function
Cooperates with MD-2 and TLR4 to mediate the innate immune response to bacterial lipopolysaccharide
Mouse anti Human CD14 Antibody, Monoclonal (UCHM1), could be used for Flow and so on.
Application:
Flow: < 0.5 μg/100w cells
Protein Function
Cooperates with MD-2 and TLR4 to mediate the innate immune response to bacterial lipopolysaccharide
Mouse anti Human CD4 Antibody, Monoclonal (RPA-T4), could be used for Flow and so on.
Application
Flow: < 0.5 μg/100w cells
Protein Function
Accessory protein for MHC class-II antigen/T-cell receptor interaction. May regulate T-cell
Mouse anti Human CD4 Antibody, Monoclonal (RPA-T4), could be used for Flow and so on.
Application
Flow: < 0.5 μg/100w cells
Protein Function
Accessory protein for MHC class-II antigen/T-cell receptor interaction. May regulate T-cell
CDP571 (anti-TNFa) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA).Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
CDP571 (anti-TNFa) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA).Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
CDP571 (anti-TNFa) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA).Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
CDP571 (anti-TNFa) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA).Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
CDP571 (anti-TNFa) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA).Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
CDP571 (anti-TNFa) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA).Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
CDP571 (anti-TNFa) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA).Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
CDP571 (anti-TNFa) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA).Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg